Rare diseases
Investigational molecules
Locations
Hegenheimermattweg 91, 4123
Research activity includes insomnia disorder, with attention to sleep maintenance and daytime functioning in people affected by persistent sleep disruption. The portfolio also includes sleep-related studies in pediatric and adolescent populations, as well as cases where insomnia occurs alongside nocturia.
The therapeutic focus extends across adult and younger age groups, reflecting interest in sleep regulation and related quality-of-life burdens.
Idorsia Pharmaceuticals Ltd. runs clinical trials in conditions such as Fabry's disease, Insomnia, Vitiligo, Progressive multiple sclerosis, among others.
Clinical trials run by this sponsor – those enrolling participants first.
Safety and efficacy of oral ACT-777991 in adults with non‑segmental vitiligo: a randomized, double‑blind, placebo‑controlled Phase 2a trial
CzechiaA study testing ACT-1004-1239 compared to placebo for adults with progressive multiple sclerosis to measure nerve repair using MRI scans
The NetherlandsEfficacy and Safety of Lucerastat in Treatment‑Naïve Adult Male Patients with Fabry Disease
FranceTesting IDOR-1117-2520 for Adults with Moderate to Severe Chronic Plaque Psoriasis With or Without Psoriatic Arthritis
BulgariaStudy to Determine Safe and Effective Dose of Daridorexant for Treating Insomnia in Children and Adolescents Aged 10 to 18 Years
BulgariaStudy on Long-Term Safety of Oral Lucerastat for Adults with Fabry Disease
AustriaStudy on Daridorexant for Treating Insomnia in Patients with Insomnia and Nocturia
GermanyIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
